AI continues to be essential for drug development research as total investments in AI-enabled drug discovery reaches $5.2B since 2021.
AstraZeneca inks a $247 million deal with AI biotech firm Absci to develop innovative cancer-fighting antibodies, aiming to transform oncology treatment and patient outcomes.
The role of AI in drug discovery, particularly in oncology, is reshaping timelines and methodologies, promising more rapid and precise development of cancer treatments. The AstraZeneca and Absci collaboration could greatly improve cancer treatment success, particularly in lung cancer where early detection increases 5-year survival rates from 10% up to 92%.
“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover,” said AstraZeneca Senior Vice President Puja Sapra.
The partnership's future hinges on the successful integration of Absci's AI in AstraZeneca's oncology pipeline.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/astrazeneca-partners-with-ai-startup-in-247m-oncology-ai-venture"
},
"headline": "AstraZeneca Partners with AI Startup in $247M Oncology AI Venture",
"description": "AI continues to be essential for drug development research as total investments in AI-enabled drug discovery reaches $5.2B since 2021.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "The Money Game",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2023-12-12"
}
</script>